For instance, future research regarding Wnt/β-catenin signaling in CRC should focus on (1) achieving a deeper understanding of crosstalk among the AKT/PI3K, NOTCH, mTOR, and Wnt/β-catenin pathways; (2) optimizing and evaluating other natural compounds as Wnt/β-catenin inhibitors while also being highly selective to avoid unnecessary side effects; (3) identifying additional inhibitors downstream of the Wnt/β-catenin signaling pathway; and (4) considering CGA structural modifications to improve the pharmacological profile and/or the affinity for β-catenin and LRP6. This evidence concerns the gene LRP6 and colorectal carcinoma.